Florham Park, NJ, October 3, 2023
Xiromed LLC today announced the launch of EnilloRing® (etonogestrel/ethinyl estradiol vaginal ring), a generic version of Nuvaring®. EnilloRing® is a contraceptive vaginal ring.
“The launch of EnilloRing® is an exciting milestone in Xiromed’s journey to becoming a leading generic provider of women’s health care products in the United States,” commented Rob Spina, CEO of Xiromed. “Xiromed has established a comprehensive portfolio of women’s health pharmaceuticals, including oral contraceptives and transdermal gels. With the availability of EnilloRing®, Xiromed offers an additional long-term contraceptive option to patients in the U.S. We are excited for the opportunity to continue to broaden and grow the availability of contraceptive options for U.S. patients. EnilloRing® was developed at our dedicated hormonal facility, Laboratorios Leon Pharma SAU, in Leon, Spain, where it is also manufactured. This product launch demonstrates our parent company, Insud Pharma’s dedication to investing in the development of new and complex technologies to broaden our pipeline and expand our offering of new dosage forms to our customers.”
Annual sales for Nuvaring® and its generics for the 12-month period ending in July, 2023 were $528m, according to IQVIA, a leading healthcare data and analytics provider. Xiromed LLC, located in Florham Park, NJ, is the US generic division of Insud Pharma, S.L., a global pharmaceutical group headquartered in Madrid, Spain. Xiromed is focused on developing and commercializing high quality generic pharmaceutical products for the US market. In addition to its commercial portfolio of generics available in the US, Xiromed has a robust development portfolio of generic pharmaceutical products in various stages of development, including injectable, inhalation and complex generic products. Learn more at http://www.xiromed.com/usa/